MediWound (NASDAQ:MDWD) Stock Rating Lowered by Wall Street Zen

MediWound (NASDAQ:MDWD) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a research note issued on Saturday.

A number of other equities analysts have also recently commented on MDWD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Finally, Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, MediWound presently has a consensus rating of “Hold” and a consensus target price of $31.67.

MediWound Stock Down 2.4%

Shares of NASDAQ MDWD opened at $17.03 on Friday. The business’s 50 day moving average price is $17.70 and its two-hundred day moving average price is $17.86. The company has a market cap of $218.15 million, a PE ratio of -8.11 and a beta of 0.13. MediWound has a twelve month low of $14.14 and a twelve month high of $22.50.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. MediWound had a negative return on equity of 70.55% and a negative net margin of 140.80%.The company had revenue of $1.87 million during the quarter, compared to analysts’ expectations of $2.09 million. As a group, research analysts anticipate that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MDWD. Quarry LP bought a new stake in MediWound during the fourth quarter worth about $26,000. BNP Paribas Financial Markets increased its holdings in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 723 shares during the period. Russell Investments Group Ltd. increased its holdings in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in shares of MediWound in the 4th quarter valued at approximately $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

Key Stories Impacting MediWound

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: 2026–2027 revenue guidance raised/outlined above street expectations — the company issued a 2026 revenue target of $24M–$26M (vs. consensus ~$22.6M) and 2027 guidance of $32M–$35M (vs. consensus ~$25.8M), suggesting material top‑line growth ahead if execution stays on track. MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs
• Positive Sentiment: Clinical and manufacturing progress: EscharEx Phase III (VALUE) is advancing as planned, NexoBrid manufacturing capacity has been expanded and is operational, and management expects regulatory approvals in 2026 — these operational milestones de‑risk near‑term commercialization upside. The company also finished the year with roughly $54M in cash. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Company filed its Form 20‑F for fiscal 2025 (routine disclosure). This is standard compliance and provides more detail for investors but is not a catalyst by itself. MediWound Files Annual Report on Form 20-F
• Neutral Sentiment: Earnings call transcript and details are available for investors who want management color on 2026 assumptions and the EscharEx program; use this to judge credibility of guidance and timing of approvals. MediWound (MDWD) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed expectations — reported quarterly revenue of $1.87M vs. analysts’ ~$2.09M estimate, highlighting a small current revenue base and near‑term sensitivity to sales execution. MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Still unprofitable with wide negative margins — Q4 GAAP loss of $0.56/sh (a smaller loss than expected), but the company reported negative net margin and return on equity, underscoring continued cash burn risk until commercial scale or regulatory approvals materialize. That combination helps explain downward pressure on the stock today. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.